IMUX
Immunic, Inc.0.6004
-0.0133-2.17%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
72.22MP/E (TTM)
-Basic EPS (TTM)
-0.80Dividend Yield
0%Recent Filings
8-K
Immunic Q2 loss widens on trials
Immunic reported Q2 2025 net loss of $27.0 million, up from $21.4 million year-over-year, driven by higher R&D costs for vidofludimus calcium trials, while bolstering its balance sheet with $70.1 million in gross proceeds from financings. Phase 2 CALLIPER data showed vidofludimus calcium reducing 24-week confirmed disability worsening by 23.8% in progressive MS patients versus placebo, with stronger effects in key subgroups. Enrollment completed for phase 3 ENSURE trials in relapsing MS; top-line data due end of 2026. Cash at $55.3 million falls short of 12-month runway.
10-Q
Q2 FY2025 results
Immunic's Q2 2025 results showed operating expenses climbing 19% year-over-year to $27.1M, driven by a 17% rise in R&D to $21.4M for vidofludimus calcium trials, while G&A jumped 27% to $5.7M on personnel and legal costs; net loss widened 25% to $26.8M, or $0.20 per share, from $21.4M last year, with EPS benefiting from higher shares outstanding. Cash burn quickened to $46.4M for the half, offset by $65.5M from April and May offerings, leaving $55.3M on hand amid going concern warnings. Positive CALLIPER data cut disability risk 30% in progressive MS patients, and ENSURE enrollment wrapped up. Yet Nasdaq delisting looms if shares stay below $1.
8-K
Immunic grants 35M SARs
Immunic, Inc. authorized up to 35 million stock appreciation rights on July 7, 2025, including 22 million for executives, exercisable starting August 1, 2026, at $0.77 per share—the day's closing price. These SARs, intended for share settlement pending stockholder approval to expand the 2019 equity plan, hinge on warrant exercises and private placement tranches. This move incentivizes leadership amid funding milestones. Yet dilution looms if approved.
8-K
Nasdaq bid price warning issued
Immunic, Inc. received a Nasdaq notice on June 27, 2025, for failing to maintain a $1.00 minimum bid price over 30 consecutive business days, triggering Item 3.01 disclosure. The company has until December 24, 2025, to lift its stock price above $1.00 for 10 straight business days and avoid delisting. While trading continues uninterrupted, Immunic is eyeing options like a reverse stock split. No guarantees of compliance.
8-K
Immunic boosts equity plan shares
Immunic's stockholders approved an amendment to its 2019 Omnibus Equity Incentive Plan on June 4, 2025, boosting authorized shares by 7 million to 26.4 million total. This bolsters talent retention amid biotech talent wars. Directors Neermann, Howson, and Phillips were elected; Baker Tilly ratified as auditors. Equity pool expansion aids hiring key personnel.
ABVX
Abivax SA
110.98-6.93
HCWB
HCW Biologics Inc.
1.78-0.09
IMA
ImageneBio, Inc.
6.25+0.08
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNM
Immunome, Inc.
23.48+0.84
IMRX
Immuneering Corporation
5.74-0.04
IMTX
Immatics N.V.
10.09+0.11
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
IMVT
Immunovant, Inc.
26.61+0.61
INMB
INmune Bio Inc.
1.89-0.02